FDA warned Natural Ophthalmics that six eye drop products are unapproved new drugs sold without FDA approval.
What happened
FDA reviewed https://natoph.com/ in August 2023. It found the site offering six eye drop products with claims to relieve dry eye, allergy symptoms, and cataract and to support eye tissues. FDA said the products are unapproved new drugs and that selling them in interstate commerce violates the law.
What FDA found
The website claims the eye drops treat dry eye, allergy symptoms, and cataract, so FDA treats them as drugs.
FD&C Act section 201(g)(1), 21 U.S.C. 321(g)(1)The products are new drugs because they are not generally recognized as safe and effective for their claimed uses.
FD&C Act section 201(p), 21 U.S.C. 321(p)No FDA-approved application is in effect for any of the six eye drop products.
FD&C Act section 505(a), 21 U.S.C. 355(a)Introducing or delivering the products for interstate commerce violates the law.
FD&C Act sections 301(d) and 505(a), 21 U.S.C. 331(d) and 355(a)Labeling the products as homeopathic does not exempt them from drug approval or other requirements.
FD&C Act section 201(g)(1), 21 U.S.C. 321(g)(1)
What FDA wants
FDA asks Natural Ophthalmics to notify it in writing within 15 working days of the steps taken to correct the violations, including explanations, prevention steps, and supporting documents; if it disagrees, it should send reasoning and evidence. If correction cannot be completed in that time, it must state why and give a completion date.
Who should pay attention
- brands or retailers selling homeopathic eye drops
- consumers using dry eye, allergy, or cataract eye drops
- ophthalmic product marketers making disease-treatment claims
This is a summary. Read the original letter on fda.gov.